STENGONE CARMINE N. (CEO and President) sold 2.6% of their position (400.00 shares) of CONTINEUM THERAPEUTICS, INC. on the open market
Open‑market sale worth $6.4K — a minor trim. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 2/13/2026ACC: 0001437749-26-004126
DirectorOfficer· CEO and President
Since Feb 2026
-400.00
Net shares
Net seller
$6.4K
Total sold
1
Open market trades
0B · 1S
3
Total transactions
400.00 acquired · 800.00 disposed
Non-Derivative Transactions2
Class A Common Stock
Direct
Shares
+400.00
Price / share
$1.26
Trade value
$504.00
% of position
2.7%
2/11/2026
14.95K→15.35K
Class A Common Stock
Direct
Shares
−400.00
Price / share
$16.00
Trade value
$6.40K
% of position
2.6%
2/11/2026
15.35K→14.95K
Total
Net shares
+0.00
Net value
-$5.90K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Class A Common Stock Direct | 2/11/2026 | M · Option Exercise | +400.00 | $1.26 | $504.00 | 2.7% | 14.95K | 15.35K |
| Class A Common Stock Direct | 2/11/2026 | S · Sale | −400.00 | $16.00 | $6.40K | 2.6% | 15.35K | 14.95K |
| Total | +0.00 | -$5.90K | ||||||
Derivative Transactions1
Stock Option (right to buy)
Direct
Converts to
Class A Common Stock
400.00 shares
Shares
−400.00
Strike price
1.26
Held after
128.02K
Exercisable
—
2/11/2026
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Stock Option (right to buy) Direct | Class A Common Stock400.00 shares | 2/11/2026 | M · Option Exercise | −400.00 | 1.26 | — | 128.02K |